ALX ONCOLOGY HLDGS INC's ticker is ALXO and the CUSIP is 00166B105. A total of 58 filers reported holding ALX ONCOLOGY HLDGS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 2.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,704 | -53.0% | 1,605 | -26.4% | 0.00% | – |
| Q2 2023 | $16,379 | +11.0% | 2,181 | -33.2% | 0.00% | – |
| Q1 2023 | $14,753 | -80.9% | 3,264 | -52.4% | 0.00% | – |
| Q4 2022 | $77,267 | +18.9% | 6,856 | 0.0% | 0.00% | – |
| Q3 2022 | $65,000 | +51.2% | 6,856 | +29.1% | 0.00% | – |
| Q2 2022 | $43,000 | -32.8% | 5,309 | +40.6% | 0.00% | – |
| Q1 2022 | $64,000 | -21.0% | 3,775 | 0.0% | 0.00% | – |
| Q4 2021 | $81,000 | -70.7% | 3,775 | +0.9% | 0.00% | – |
| Q3 2021 | $276,000 | +135.9% | 3,742 | +74.5% | 0.00% | – |
| Q2 2021 | $117,000 | -24.5% | 2,144 | +1.9% | 0.00% | – |
| Q1 2021 | $155,000 | +32.5% | 2,105 | +54.9% | 0.00% | – |
| Q4 2020 | $117,000 | +192.5% | 1,359 | +27.0% | 0.00% | – |
| Q3 2020 | $40,000 | – | 1,070 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| venBio Partners LLC | 9,699,925 | $163,929,000 | 36.34% |
| Logos Global Management LP | 3,011,352 | $50,892,000 | 6.60% |
| Vivo Capital, LLC | 4,220,048 | $71,319,000 | 4.91% |
| Samsara BioCapital, LLC | 262,786 | $4,441,000 | 1.12% |
| Cormorant Asset Management, LP | 712,079 | $12,034,000 | 0.92% |
| Pier Capital, LLC | 394,443 | $6,666,000 | 0.85% |
| Redmile Group, LLC | 772,397 | $13,054,000 | 0.41% |
| Artal Group S.A. | 500,000 | $8,450,000 | 0.35% |
| Nan Fung Group Holdings Ltd | 41,950 | $709,000 | 0.34% |
| Orbimed Advisors | 621,700 | $10,507,000 | 0.17% |